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Effects of ACE inhibition supplementary to beta blockers and diuretics
in early diabetic nephropathy. Angiotensin converting enzyme (ACE)
inhibition has shown promising results in diabetic nephropathy, but
long-term results on survival are not available. In a cohort of patients
receiving antihypertensive treatment predominantly consisting of beta
blockers in combination with diuretics, support for an improved sur-
vival has been presented. Addition of ACE inhibition to such a
combination treatment may be favorable both due to the suggested
renoprotective effects of ACE inhibitors and because diuretics activate
the renin-angiotensin system. In 10 insulin-dependent diabetic patients
with early diabetic nephropathy [urinary albumin excretion rate (UAE)
<1000 g/min], who were receiving continuous therapy with meto-
prolol and bendroflumethiazide, a double-blind crossover study with
four months addition of ramipril 5 mg (Ramace®) and placebo was
conducted. UAE (radioimmunoassay) and fractional albumin excretion
were significantly reduced after the four months of ramipril administra-
tion [UAE: 114.! x/-v 1.3 (geometric mean x/± confidence factor]
versus 174.6 xI-v 1.2 g/min, 2P < 0.005). Renal plasma flow (clearance
of °'I-hippuran) tended to increase [497 25 (mean sE) vs. 464 28
ml/min/1.73 m2, 2P = 0.081, while GFR ('251-iothalamate) stayed
unchanged (121 8 vs. 120 9 ml/min/l.73 m2). Mean arterial pressure
during clearance studies fell moderately (95 3 vs. 101 I mm Hg, 2P
< 0.05) and renal resistance was decreased (2P < 0.03). ACE activity
was suppressed in all patients. Twenty-four-hour ambulatory blood
pressure measurements were not significantly different after the two
periods (daytime averages: 91 2 vs. 93 2, nighttime 80 2 vs. 84
3 mm Hg). Echocardiography showed no changes. It can be con-
cluded that addition of an ACE inhibitor reduces VAE in patients on
ongoing antihypertensive therapy. Qualitatively the renal response to
ACE inhibition in the present patients on beta blocker and thiazide
treatment corresponds to the hemodynamic effects observed in previ-
ously untreated diabetic patients.
The use of angiotensin converting enzyme (ACE) inhibitors
as antihypertensive therapy in insulin-dependent diabetes has
shown promising results, yet the role of this class of drugs is not
finally established. Theoretically ACE inhibition may be of
specific benefit in diabetic nephropathy due to the apparent
capability of such treatment to reduce glomerular hydrostatic
pressure difference (P). In experimental models of diabetes in
rats a lowering of efferent arteriolar resistance accompanied by
a reduction of P has been demonstrated [1, 2], and clinical
studies have likewise indicated that the renal effects of ACE
inhibitors may include a lowering of P also in the absence of a
systemic blood pressure reduction [3—5]. Besides a possible
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specific influence on renal hemodynamics the use of ACE
inhibitors in diabetes has been suggested since these drugs
appear to be without significant influence on glucose metabo-
lism [6—8]. Experiences on efficacy of ACE inhibitors in overt
diabetic nephropathy indicate that the rate of decline of GFR
can be reduced to a level comparable to that reported for
combination treatments with selective beta blockers and diuret-
ics [9]. In incipient diabetic nephropathy only indirect measures
of efficacy such as effects on progression of albuminuria and
hypertension can be obtained unless very long term studies are
conducted. ACE inhibition has proved to reduce urinary albu-
min excretion rate (UAE) in such patients [3, 5, 10], and
progression of albuminuria to a level corresponding to overt
nephropathy has been delayed or prevented [3, 10].
However, long-term experiences concerning survival during
ACE inhibition in diabetic nephropathy are not available and so
far support for an improved survival has only been presented
for 'conventional' antihypertensive regimes including predom-
inantly diuretics and beta blockers and in a few cases vasodi-
lators [Il]. It is possible that addition of an ACE inhibitor to a
combination treatment with selective beta blockers and thiazide
diuretics might have beneficial renal effects both due to the
suggested specific renoprotective effects of ACE inhibition as
well as to a counteracting effect on the activation of the
renin-angiotensin-aldosterone system, which may be caused by
administration of diuretics [12]. Furthermore, a combination
therapy would allow low dosages of each drug to be used,
thereby limiting the risk of side effects. The aim of the present
double-blind, placebo-controlled study was therefore to inves-
tigate whether a well-established antihypertensive therapy con-
sisting of a selective beta blocker and a thiazide diuretic may be
improved by addition of an ACE inhibitor. UAE was consid-
ered the main efficacy variable. Since cardiac abnormalities
including diastolic dysfunction and ventricular hypertrophy are
frequently found in insulin-dependent diabetic patients [13—161,
echocardiographic assessment of cardiac involvement and re-
sponse to treatment was also studied.
Methods
Patients
Ten insulin-dependent diabetic (IDDM) patients participated
in the study. Inclusion criteria were: a) early diabetic nephrop-
athy (UAE during clearance studies below 1000 sg!min); b) age
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Sex (M/W)
Age years
Diabetes duration years
Body mass index kg/rn2
Insulin dose U/kg
HbAIC %
Blood pressure mm Hg SBP/
DBP
Glonierular filtration rate
rnl/min/1.73 m2
Urinary albumin excretion rate
g/min
Retinopathy (N/B/P)
Metoprolol daily dose mg
Bendroflumethiazide daily dose
mg
Data are presented as mean (range) (for urinary albumin excretion
rate geometric mean). Abbreviations are: SBP, systolic blood pressure;
DBP, diastolic blood pressure; N/B/P, none/background/proliferative.
below 55 years; and c) ongoing combination treatment with a
selective beta blocker (metoprolol; Selo-Zok®, Astra Hassle
AB, Sweden) and a thiazide diuretic (bendroflumethiazide)
(Centyl c. KCL®, Leo, Denmark) for at least three months prior
to inclusion. Patients with a pre-study blood pressure below 115
mm Hg systolic and 80 mm Hg diastolic were not included in the
study. Patient characteristics at baseline are given in Table 1.
Two patients had baseline GFR values below the normal range
in the laboratory (65 and 91 mlIminIl.73 m2, respectively) and
one patient was clearly hyperfiltering. Prior to the present study
patients had been on antihypertensive treatment with beta
blocker for in mean six years (range: 4 months to 14 years) due
to persistent microalbuminuria [N = 6, systolic/diastolic blood
pressure before start of antihypertensive treatment: 136 (128 to
151)189 (70 to 97) mm Hg (mean and range)] or overt nephrop-
athy [N = 2, blood pressure prior to treatment: 146 (125 to
175)191 (70 to 90)]. In one patient beta blocker treatment was
initiated due to hypertension without knowledge of the albumin
excretion (later found to be at microalbuminuric level). Thi-
azide diuretics were added later. Patients gave informed con-
sent and the study was approved by the local ethical committee.
Design
The investigation was conducted as a double-blind crossover
study. After a kidney function test at baseline patients were
randomized to receive the ACE inhibitor ramipril (Ramace®,
Astra Hassle) and placebo in random order each for four
months in addition to the ongoing treatment with beta1 blocker
and thiazide. The dose of ramipril (/placebo) was increased
gradually at two week intervals from 1.25 to 2.5, and then 5 mg
daily according to the blood pressure level (no increase from 2.5
to 5 mg in case of blood pressure measurements in the clinic
below 110/70 mm Hg). All patients received the final dose of 5
mg. Kidney function was investigated at the end of each of the
two study periods. In addition 24-hour ambulatory blood pres-
sure measurement and echocardiography were performed at
baseline and at the end of each study period.
Methods
Glomerular filtration rate (GFR) and renal plasma flow (RPF)
were measured by constant infusion technique using I251
iothalamate and '311-hippuran, respectively, as markers [17].
Patients fasted overnight before the clearance study, no morn-
ing dose of insulin was given, but patients took their usual
antihypertensive medicine including the study drug. To pro-
mote diuresis patients drank 250 ml of water every 20 minutes
from 2 hours before (at 7:00 a.m.) and throughout the investi-
gation. After a priming dose, isotope infusion was given for 55
minutes before five 20-minute clearance periods were per-
formed. UAE was measured by radioimmunoassay [18] on
samples from the clearance study. In the first clearance period
serum sodium, potassium, urea, creatinine and albumin as well
as urine electrolytes were measured by conventional laboratory
techniques. HbAIC was measured by HPLC [19] (normal range
4.4 to 6.4%). Blood glucose was measured in the first and last
clearance period (standard enzymatic technique) and ACE
activity and hormones in the fourth clearance period. Plasma
ACE activity was measured by HPLC (Medi-Lab a.s., Copen-
hagen) [201 (normal range 9 to 53 U/liter) and immunoreactive
angiotensin II (Ang II; normal range 13 to 27 pmol/liter),
aldosterone (195 to 612 pmol/liter) and renin activity (0.51 to
2.64 ng angiotensin I/ml/hr) by radioimmunoassay kits from
Buhlman Laboratories AC (Basel, Switzerland) [21—23], Diag-
nostic Products Corp. (Los Angeles, California, USA) [24] and
Biodata Maia (Italy) [25], respectively (hormone measurements
were performed at Karolinska Institute, Clinical Research
Center, Huddinge, Sweden). In the middle of each clearance
period heart rate and blood pressure (standard sphygmoma-
nometer, Korotkoff phase V for diastolic pressure) were as-
sessed.
Twenty-four-hour ambulatory blood pressure measurements
were performed by oscillometry using a portable automatic
monitor, SpaceLabs model 90202 (Redmond, Washington,
USA). The equipment was programmed to measure blood
pressure every 20 minutes from 6 a.m. to 12 p.m. In the night
one measurement per hour was performed. The application of
this procedure for ambulatory blood pressure measurements in
IDDM is described in detail elsewhere [26, 27].
Standard M-mode echocardiography was used to measure
left ventricular systolic (LVID) and diastolic (LVIDd) dimen-
sions, interventricular septal (IVS) and posterior wall (LVPW)
thickness and left ventricular ejection time (LVET). Left ven-
tricular systolic function was estimated as fractional shortening
[FS = (LVIDd — LVIDS)/(LVIDd x 100)] and mean velocity of
circumferential shortening (Vcf = FS/LVET). Left ventricular
diastolic function was assessed from the two mitral valve inflow
signals on pulsed Doppler echocardiograms, that is, left ven-
tricular peak early filling (E wave) and peak late filling (A
wave). The E:A ratio was subsequently calculated, Mean
values from five consecutive cardiac cycles were derived.
Calculations and statistical methods
GFR and RPF were adjusted to 1.73 m2 body surface area.
Filtration fraction (FF) was calculated as GFR/RPF, total renal
resistance (TRR) as mean arterial pressure (MAP)/RPF, frac-
tional albumin excretion (A1b) as UAE/(GFR x plasma albu-
min) and fractional excretion of electrolytes as clearance of
electrolyte x 100/GFR. Results on normally distributed values
are given as mean SE. UAE and ®Alb were log transformed
prior to statistical analysis to achieve normal distribution, and
results are therefore given as geometric mean x/÷ confidence
Table 1. Patient characteristics at baseline
9/I
37 (27—48)
24 (15—35)
25.5 (21.0—30.5)
0.67 (0.39—0.99)
8.8 (7.2—10.4)
133/85 (125—152/75—101)
119 (65—163)
115.2 (56.0—449.9)
0/8/2
140 (50—200)
3.8 (2.5—7.5)
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factor. Results on hormone concentrations are given as medians
and first and third quartile. Individual results on kidney function
variables were calculated as mean values from the five clear-
ance periods. Comparison of results from the ramipril and
placebo period was performed by Student's (-test for paired
comparison or by Wilcoxon's rank sum test. No carryover or
period effects could be demonstrated with respect to UAE,
MAP and RPF. A 2P level of less than 0.05 was considered
statistically significant.
To analyze ramipril induced changes in kidney function and
blood pressure ( — values = placebo — ramipril) parametric
correlation analysis (Pearson's r) and (when hormone values
were included in calculations) non-parametric rank correlation
analysis was performed. For changes in logUAE and MAP also
multiple regression analysis after forward stepwise selection of
independent variables was carried out. As possible independent
variables zMAP, HbA1ç, AFF, Amean blood glucose (during
kidney function tests), Abody weight, AACE activity and Ahor-
mone concentrations were included.
Results
Kidney funcilon
In all but one patient UAE was reduced during ramiprif
treatment compared to placebo. The geometric mean was 114.1
x/÷ 1.3 (confidence factor) compared to 174.6 xI± 1.2 gImin
after the placebo period (2P < 0.005; Fig. 1). Also OAlb
declined during ramipril treatment (0.026 X/± 1.4 vs. 0.039 xI±
1.3, 2P < 0.02). Results on renal hemodynamics are given in
Table 2. Kidney hernodynaniics in nine IDDM patientsa at the end of
four months' addition of ramipril and placebo to ongoing
antihypertensive treatment
Placebo Ramipril Significance
GFR 120±9 121±8 NS
mi/min/l.73 m2
RPF 464 28 497 25 NS (2P = 0.08)
mi/mini] .73 m2
FF 0.260 0.012 0.245 0.016 NS (2P = 0.12)
TRR 0.228 0.018 0.197 0.013 2P < 0.03
mm Hg x minim!
Blood pressure
MAP measured during the clearance studies was moderately
reduced with ramipril, 95 3 vs. 101 1 mm Hg (2P < 0.05).
Results of ambulatory MAP measurements are shown in
Figure 2. MAP values obtained with ramipril treatment and
placebo during both daytime (91 2 vs. 93 2 mm Hg, NS),
nighttime (80 2 vs. 84 3 mm Hg, NS; 2P = 0,13) and a 24
hour period (88 2 vs. 91 2 mm Hg, NS, 2P = 0.13) were not
statistically significantly different, although the numerical mean
values were slightly lower during ramipril treatment.
Differences between the MAP results obtained auscultatoric
during kidney function tests and those obtained during ambu-
latory oscillometric daytime recordings were closely and nega-
tively correlated to the absolute GFR level (at baseline, placebo
and ramipril investigations; r between —0.86 and —0.88, P <
0.005).
Echocardiography
Table 3 gives the results of echocardiography at the end of
each treatment period. No significant differences in echocardio-
graphic parameters were demonstrated between the ramipril
and the placebo period.
Metabolic control
HbA at the end of the ramipril and placebo periods was not
significantly different (8.5 1.5 vs. 8.8 0.4%, NS). Also mean
blood glucose during kidney function tests (11.4 1.4 vs. 11.5
1.2 mmol/liter, NS), insulin dose (0.67 0.05 vs. 0.65 0,05
U/kg, NS) and body weight (79.1 2.9 vs. 80.4 2.4 kg, NS)
were comparable under ramipril and placebo treatment.
UAE, pg/rn/n
800.
400
200 -l
175
100 -
50
800
400
200
- 100
Data as mean SE. Abbreviations are: GRF, glomerular filtration
rate; RPF, renal plasma flow; FF, filtration fraction; TRR, total renal2 — resistance = MAP/RPF; NS, not significant.
a Clearance investigation was not performed in one patient due to
technical reasons.0 E
.114
Table 2. The mean value of RPF was higher on ramipril than on
placebo though the difference did not reach statistical signifi-
50 cance (2P = 0.08). GFR showed similar values at the end of the
two periods. Accordingly mean FF was lower during ramipril,
but no statistically significant reduction was noted (2P = 0.12).
TRR declined (2P < 0.03). No differences in fractional sodium
(1.88 0.14 vs. 1,94 0.15%) and potassium excretion were
Fig. 1. Urinary albumin excretion rate (UAE) at the end of four observed. Serum concentration of sodium, potassium (4.4 0.2
months' addition of ramipril 5 mg daily and placebo to ongoing vs. 4.3 0.1 mmol/liter) and creatinine were likewise compa-
antihypertensive therapy with a selective beta-blocker and a thiazide
diuretic in ten IDDM patients with early diabetic nephropathy. = rable after ramipril and placebo.
geometric mean. 2P < 0.005.
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150
S BP
DBP
LVIDd mm 45.8 0.6 45.0 0.7
LVID mm 26.7 0.9 27.4 1.0
IVS mm 10.5 0.4 11.0 0.5
LVPW mm 10.1 0.2 10.4 0.4
FS mm 38.4 4.5 39.1 1.7
Vcfcirc/sec 1.38 0.06 1.32 0.09
E-wave rn/sec 0.72 0.03 0.74 0.04
A-wave rn/sec 0.53 0.03 0.55 0.03
E:A ratio 1.37 0.10 1.38 0.10
Data as mean s. Abbreviations are: LVIDd, left ventricular
diastolic dimension; LVID, left ventricular systolic dimension; IVS,
interventricular septal thickness; LVPW, left ventricular posterior wall
thickness; FS, fractional shortening; Vcf, mean velocity of circumfer-
ential shortening; E-wave, left ventricular peak early filling; A-wave,
left ventricular peak late filling. Comparisons between placebo and
ramipril values: NS.
Hormonal parameters and ACE activity
ACE activity declined in all patients during the ramipril
treatment. The mean value fell from 32 2 on placebo to 8
1 U/liter on ramipril (2P < 0.001). No significant changes in
hormone levels were seen, although the median value of renin
activity after four months of ramipril was increased [ramipril:
3.29 (2.68 to 6.08) vs. placebo: 2.53 (2.30 to 4.96) ng angiotensin
I/mi/hour, NSI and median value of aldosterone decreased [193
(127 to 219) vs. 213 (132 to 297) pmol/liter, NSI. The median
value of immunoreactive Ang II was 13.7 (12.0 to 26.2) pmol/
liter on ramipril and 14.5 (8.6 to 18.5) pmol/iiter on placebo (2P
= 0.08).
Correlations
Changes in (JAE. MogUAE was closely correlated to differ-
ences in MAP values obtained during the kidney function
studies (zMAP) (r = 0.84, P < 0.005; Fig. 3). Also an associ-
ation to zbody weight was indicated (r = 0.68,P < 0.03; Fig. 4).
In a multiple regression analysis with Mog UAE as the depen-
dent variable, AMAP and IHbAIç were identified as factors
with independent association (positive and negative, respec-
tively) to LMogUAE (Table 4).
Changes in MAP during clearance studies. Simple correla-
tion analysis showed a negative association between differences
in mean blood glucose and LMAP (r =
—0.68, P < 0.05), and
multiple regression with MAP as the dependent variable
demonstrated that besides a negative association to Lmean
blood glucose, a positive correlation to body weight was
present (R2 = 0.81, analysis of variance: P < 0.005).
Other correlations. LFF was negatively correlated to 1mean
blood glucose (r = —0.75, P < 0.05), Borderline significant
correlations between aIdosterone and iMogUAE (rho = 0.61,
P = 0.08) and aldosterone and body weight (rho 0.62, P =
0.06) were noted. The baseline level of renin activity was
positively correlated to baseline MAP (rho = 0.71, P 0.04).
Discussion
The present study demonstrates that addition of the ACE
inhibitor ramipril to ongoing antihypertensive treatment with a
selective beta blocker and a thiazide diuretic reduces UAE and
®Alb considerably in IDDM patients with early diabetic
nephropathy. Along with the reduction in UAE a decrease in
blood pressure at kidney function tests was observed. Renal
resistance was reduced while RPF tended to rise and GFR
remained unaltered. These results would be compatible with a
reduction mainly in efferent arteriolar resistance and a conse-
quent fall in the glomerular hydrostatic pressure difference, P.
Angiotensin II is known to reduce the ultrafiltration coefficient,
Kf [28, 291, while ACE inhibition appear to increase Kf [2].
Thus the unchanged level of GFR indicates that zP most likely
was lowered. The correlation between zMAP and MogUAE
may accordingly express that changes in renal hemodynamics
during ACE inhibition allowed a reduction in systemic blood
E
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Fig. 2. Twenty-four hour profile of hourly
mean systolic and diastolic blood pressure at
the end of four months' addition of ramipri! 5
mg daily (0) and placebo (•) to ongoing
antihypertensive therapy with a selective beta-
blocker and a thiazide diuretic. Vertical bars
represent standard errors. No statistically
significant differences exist between daytime,
nighttime or 24 hour averages on ramipril
versus placebo. N = 10.
Table 3. Echocardiographic parameters at the end of four months'
addition of ramipril and placebo to ongoing antihypertensive
treatment
Placebo Ramipril
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Log UAE
Fig. 4. Correlation between individual differences in urinary albumin
excretion rate (&0gUAE) and body weight (zbody weight) after addi-
tion of ramipril versus placebo to ongoing antihypertensive therapy in
ten IDDM patients. = placebo — ramipril. r = 0.68; 2P < 0.03.
pressure to be transmitted to the glomeruli. An explanation that
Mog UAE was not correlated to zFF (and that a decline in FF
could not be demonstrated) may be that the expected associa-
tion between a reduction in P and FF is likely to have been
interfered with by a rise in K5. Furthermore, IFF seemed to be
influenced (confounded) by the level of blood glucose.
Table 4. Associations to reduction in IogUAE with four months of
addition of ramipril to ongoing antihypertensive treatment
Independent variable Coefficient SE Significance level
MAP ,nm Hg 0.019 0.004 0.001
HbAI % —0.083 0.028 0.023
Intercept 0.094 0.03 1 0.020
R2 (Adjusted for degrees of freedom) = 0.83; analysis of variance for
the full regression: P = 0.0009.
Also variation in body weight appeared to be relevant to the
reduction in UAE as illustrated by the correlation analysis (Fig.
4). With short-term administration of ACE inhibitors a decrease
in body weight has been observed [30], and the weight loss
ascribed to the natriuretic effect of these agents. Although no
change in mean body weight was noted in the present study, it
can be suggested that—in accordance with previous results
[31]—inhibition of ACE might have reduced a tendency
towards extracellular volume expansion in some of these neph-
ropathic patients. A reduction of Ang II levels during ACE
inhibition could be assumed to increase excretoric capability,
such as during acute sodium or volume loads [32, 33]. An
influence on fluid homeostasis of ramipril would be in accor-
dance with the demonstration of a correlation between zbody
weight and LMAP and the borderline significant association
between zaldosterone and iMogUAE.
The renal effects of ACE inhibition in diabetes may be more
pronounced in cases of poor metabolic status. This has been
suggested by studies dealing with acute hemodynamic effects of
ACE inhibition in normoalbuminuric [34] and in microalbumin-
uric IDDM patients (unpublished data, Klavs W. Hansen), and
would be in accordance with findings in the present study. Thus
multiple regression analysis demonstrated that HgA1 was
inversely associated with the reduction in logUAE induced by
ACE inhibition (that is, those patients who 'by chance' were in
a poorer metabolic control during active treatment than during
placebo showed the largest reduction in UAE). ACE-inhibition
in itself does not appear to influence metabolic status [8, 35, 36].
Qualitatively the effects of ACE inhibition on albumin excre-
tion and renal hemodynamics observed in the present group of
patients were similar to results of ACE inhibition given as
monotherapy in IDDM patients with incipient nephropathy [3,
5, 10, 37, 38] and also in patients with normoalbuminuria [4].
This may be also notable since placebo (and baseline) renin and
Ang II levels actually were found to be relatively low consid-
ering the diuretic treatment. It is possible that the beta blockade
might have suppressed the renin level [30, 39].
The mechanisms behind pharmacological reduction in UAE
in diabetic nephropathy appear to differ markedly for ACE
inhibitors and beta blockers, respectively. During acute beta
blockade in diabetic and non-diabetic subjects, total peripheral
resistance and renal resistance have been reported to increase
and RPF to decline along with a rise in FF [37, 40, 41]. It
appears that these hemodynamic changes are attenuated during
long-term treatment, but still it can be anticipated that UAE is
lowered primarily due to a reduction in cardiac output and
thereby in blood pressure, while renal resistance stays un-
changed or increases slightly [30, 42—44]. This contrasts to the
lowering of renal resistance and, as it seems, in specific of
efferent arteriolar resistance and P brought about by ACE
20
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Fig. 3. Correlation between individual changes in urinary albu,nin
excretion rate (i.JogUAE) and mean arterial pressure during clearance
studies (AMAP) after addition of ramipril versus placebo to ongoing
antihypertensive therapy in ten IDDM patients. = placebo — rami-
pril. r = 0.84; 2P < 0.005.
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inhibition (as monotherapy or supplementary to other antihy-
pertensives). If judged exclusively from these differences in
hemodynamic effects, ACE inhibitors might be expected to
reduce UAE more efficiently than beta blockers (per mm Hg),
and the comparative study by Björck and coworkers indicated
the presence of such a difference between a beta blocker and an
ACE inhibitor [451. However renal effects of beta blockers may
also include consequences from the possible reduction of renin
activity. With the present combination treatment it can be
suggested that possible unfavorable effects of beta blockade on
renal hemodynamics will be counteracted by addition of an
ACE inhibitor. Besides the likely effects on P, it has been
suggested that ACE inhibitors may influence size-selective
membrane properties of the glomerular barrier [46] and may
suppress glomerular growth [47, 48].
Blood pressure results from the two procedures for measure-
ment, namely auscultatoric measurements during the kidney
function tests and ambulatory measurements by oscillometric
technique, were not similar. The absence of significant differ-
ences in the ambulatory blood pressure levels between placebo
and ramipril suggests that blood pressure in the present patients
was adequately controlled at baseline by the ongoing antihyper-
tensive treatment. Thus no further reduction, or only a minor
reduction, was obtainable during addition of ramipril. Still, it is
possible that the dose and/or administration of the thiazide had
relevance to the difference in blood pressure results with the
two procedures. All patients had a morning dose of thiazide
which, when taken together with the ACE inhibitor, might
actually have given rise to a modest decline in blood pressure
during the late morning [49, 50]. This would be in accordance
with the blood pressure measurements during kidney function
tests and with the ambulatory 24-hour curves (Fig. 2).
Concerning blood pressure measurements during the clear-
ance studies, it appears that the water load might constitute a
blood pressure 'stress' situation caused by acute volume load
and possible volume expansion. With the reservation that
figures from auscultatoric and oscillometric measurements may
not be directly comparable, MAP at the placebo situation
seemed higher during the clearance studies than during daytime
ambulatory recordings (101 1 vs. 93 2 mm Hg, 2P < 0.01).
This difference between the two MAP measures appeared to be
strongly inversely correlated to baseline GFR level, suggesting
that a substantial blood pressure rise during water load may be
a pathological response characterizing patients with reductions
in GFR and thereby a reduced capacity for pressure diuresis. It
seemed that addition of ramipril abolished or reduced the blood
pressure elevation brought about by water load (95 3 vs. 91
2 mm Hg, NS), but still a strong negative correlation between
differences in MAP with the two measurements and absolute
GFR levels was present.
The mean baseline echocardiographic data for left ventricular
wall thickness and systolic function were within the range of
values reported in control subjects [51], although some patients
obviously showed definite echocardiographic left ventricular
hypertrophy. The indices of diastolic function at baseline re-
vealed relatively high A-wave velocities as reported in diabetic
patients [13—15], but they did not differ clearly from reported
normal values [13—15, 52], and the E:A ratio was preserved.
These findings may well reflect a beneficial effect of the blood
pressure reduction from combined beta blocker and diuretic
treatment on wall thickness and on left ventricular diastolic
function otherwise reported to be altered in early nephropathy
[13—15]. Although no significant changes in echocardiographic
parameters were found following the addition of ramipril, no
conclusion as to a possible beneficial effect of ACE inhibitors
can be drawn, particularly in view of the baseline data, the
patient number and the ongoing treatment with a beta blocker
and a diuretic.
At present no 'final' recommendations on antihypertensive
therapy in incipient and overt nephropathy exist. As mentioned
there are strong supports that effective blood pressure reduc-
tion with beta blockers and diuretics improves survival in
diabetic nephropathy [lii. Also pathogenetic features in diabe-
tes argues for their use. Thus with respect to beta blockers a
reduction of cardiac output may be favorable in order to avoid
high cardiac output hypertension with subsequent risk of hy-
pertrophy of arterial smooth muscle cells [33, 53]. Hypertension
with high cardiac output may be an increased risk in IDDM due
to autonome neuropathy with decreasing vagus activity as one
of the first manifestations. Furthermore, beta blockade may
offer general cardioprotection [54—56] such as by reducing fatal
arrhythmias [6]. The main reason for the use of diuretics in
diabetic nephropathy is to counterbalance the characteristic
sodium and volume retention which are likely to be involved in
the development of hypertension [6, 7, 12, 57—59].
Although long-term studies on survival in diabetic nephrop-
athy during ACE inhibitor treatment are awaited, and accord-
ingly the importance of pharmacological reduction of UAE
lacks confirmation, addition of such agents to a combination of
beta blockers and diuretics seems well founded. Thus, in
summary there are strong indications of specific renoprotective
effects of ACE inhibitors. UAE may be further lowered com-
pared to the level during previous antihypertensive therapy. P
is likely to be reduced, and the effects on renal hemodynamics
may apparently counteract renal vasoconstriction brought
about by beta blockade. Finally increased activity of the
renin-angiotensin-aldosterone system caused by diuretics may
be blunted and renal excretory capability for sodium and
volume excretion improved.
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